{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:27Z","timestamp":1790707227306,"version":"4.1.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T00:00:00Z","timestamp":1358899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0053100","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T21:58:44Z","timestamp":1358978324000},"page":"e53100","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Resistance after Chronic Application of the HDAC-Inhibitor Valproic Acid Is Associated with Elevated Akt Activation in Renal Cell Carcinoma In Vivo"],"prefix":"10.1371","volume":"8","author":[{"given":"Eva","family":"Juengel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Makarevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Tsaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman A.","family":"Blaheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"A Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.juro.2008.04.136","article-title":"Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors","volume":"180","author":"K Kanao","year":"2008","journal-title":"J Urol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1111\/j.1349-7006.2010.01717.x","article-title":"Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma","volume":"101","author":"D Mosashvilli","year":"2010","journal-title":"Cancer Sci"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/j.1582-4934.2008.00603.x","article-title":"Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix","volume":"13","author":"J Jones","year":"2009","journal-title":"J Cell Mol Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-07-0014","article-title":"Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma","volume":"13","author":"Y Kato","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/j.1582-4934.2008.00436.x","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo","volume":"13","author":"J Jones","year":"2009","journal-title":"J Cell Mol Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3109\/07357907.2011.590568","article-title":"A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma","volume":"29","author":"JD Hainsworth","year":"2011","journal-title":"Cancer Invest"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","article-title":"A phase II study of depsipeptide in refractory metastatic renal cell cancer","volume":"5","author":"WM Stadler","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1007\/s12032-010-9700-3","article-title":"A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results","volume":"28","author":"J Coronel","year":"2011","journal-title":"Med Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"PN Munster","year":"2011","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/bjc.2011.527","article-title":"Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours","volume":"106","author":"R Pili","year":"2012","journal-title":"Br J Cancer"},{"key":"ref12","article-title":"Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors","author":"JH Strickler","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.10338","article-title":"Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma","volume":"94","author":"T Migita","year":"2002","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11255-008-9442-8","article-title":"Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma","volume":"41","author":"A Pertia","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00428-005-1262-y","article-title":"Concomitant deregulation of HIF1alpha and cell cycle proteins in VHL-mutated renal cell carcinomas","volume":"447","author":"DJ Atkins","year":"2005","journal-title":"Virchows Arch"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/ijc.21869","article-title":"Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients","volume":"119","author":"SO Ikuerowo","year":"2006","journal-title":"Int J Cancer"},{"key":"ref17","article-title":"Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells","author":"E Juengel","year":"2012","journal-title":"Cancer Lett"},{"key":"ref18","first-page":"633","article-title":"The histone deacetylase inhibitors suberoylanilidehydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells","volume":"31","author":"A Fedier","year":"2007","journal-title":"Int J Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.juro.2009.08.085","article-title":"Phosphatidylinositol-3-kinase\/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase\/Akt inhibitors","volume":"182","author":"C Porta","year":"2009","journal-title":"J Urol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/0008-5472.CAN-05-1469","article-title":"The phosphoinositide 3-kinase\/Akt pathway: a new target in human renal cell carcinoma therapy","volume":"66","author":"C Sourbier","year":"2006","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1470-2045(09)70240-2","article-title":"Resistance to targeted therapy in renal-cell carcinoma","volume":"10","author":"BI Rini","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e27308","DOI":"10.1371\/journal.pone.0027308","article-title":"A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells","volume":"6","author":"M Bordonaro","year":"2011","journal-title":"PLoS One"},{"key":"ref23","first-page":"477","article-title":"Suppression of phosphatidylinositol 3-kinase\/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells","volume":"13","author":"M Kodani","year":"2005","journal-title":"Oncol Rep"},{"key":"ref24","article-title":"Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling","author":"C Qian","year":"2012","journal-title":"Clin Cancer Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0053100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T22:20:38Z","timestamp":1588976438000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0053100"}},"subtitle":[],"editor":[{"given":"David","family":"Loeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0053100","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,23]]}}}